198 related articles for article (PubMed ID: 35181548)
1. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
Chen MM; Roufosse F; Wang SA; Verstovsek S; Durrani SR; Rothenberg ME; Pongdee T; Butterfield J; Lax T; Wechsler ME; Stein ML; Ogbogu PU; Kahwash BM; Mathur SK; Simon D; Akuthota P; Holland N; Wetzler L; Ware JM; Guo C; Fay MP; Khoury P; Klion AD; Bochner BS
J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548
[TBL] [Abstract][Full Text] [Related]
2. Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.
Kuang FL; Khoury P; Weller PF; Wechsler ME; Klion AD
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2666-2671. PubMed ID: 37507068
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
[TBL] [Abstract][Full Text] [Related]
4. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
Williams AK; Dou C; Chen LYC
Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
6. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
7. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
8. Eosinophilic respiratory disorders and the impact of biologics.
Bernstein JS; Wechsler ME
Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
[TBL] [Abstract][Full Text] [Related]
9. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
10. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
Olaguibel JM; Sastre J; Rodríguez JM; Del Pozo V
J Investig Allergol Clin Immunol; 2022 Jun; 32(3):165-180. PubMed ID: 35522053
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging biologic therapies targeting eosinophilic disorders.
Pitlick MM; Li JT; Pongdee T
World Allergy Organ J; 2022 Aug; 15(8):100676. PubMed ID: 35983569
[TBL] [Abstract][Full Text] [Related]
13. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
Roufosse F; Kahn JE; Rothenberg ME; Wardlaw AJ; Klion AD; Kirby SY; Gilson MJ; Bentley JH; Bradford ES; Yancey SW; Steinfeld J; Gleich GJ;
J Allergy Clin Immunol; 2020 Dec; 146(6):1397-1405. PubMed ID: 32956756
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
Rothenberg ME; Roufosse F; Faguer S; Gleich GJ; Steinfeld J; Yancey SW; Mavropoulou E; Kwon N;
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2367-2374.e3. PubMed ID: 35568330
[TBL] [Abstract][Full Text] [Related]
17. Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.
Khoury P; Abiodun AO; Holland-Thomas N; Fay MP; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(1):190-195. PubMed ID: 28757367
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
Roufosse FE; Kahn JE; Gleich GJ; Schwartz LB; Singh AD; Rosenwasser LJ; Denburg JA; Ring J; Rothenberg ME; Sheikh J; Haig AE; Mallett SA; Templeton DN; Ortega HG; Klion AD
J Allergy Clin Immunol; 2013 Feb; 131(2):461-7.e1-5. PubMed ID: 23040887
[TBL] [Abstract][Full Text] [Related]
19. Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α - benralizumab.
Kosałka-Węgiel J; Milewski M; Siwiec A; Strach M; Ochrem B; Korkosz M
Cent Eur J Immunol; 2021; 46(3):395-397. PubMed ID: 34764813
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]